As more data has been made available, however, I have moderated those views. BTW, the CEGE CEO has acknowledged that any of its trials can be stopped for safety concerns, which presumably would include more fatalities in the experimental arm than the control arm, as recently occurred with NOVC's calcitrol. The context was that he was referring to stopping Vital 1 for futility because of lack of efficacy at the interim, which he said will not occur.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.